Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,226,020 papers from all fields of science
Search
Sign In
Create Free Account
SAIT301
Known as:
Anti-C-met Monoclonal Antibody SAIT301
A humanized monoclonal antibody targeting the alpha chain of the extracellular domain of human hepatocyte growth factor receptor (HGFR or c-Met…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Monoclonal Antibodies
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Phase I Trial of Anti‐MET Monoclonal Antibody in MET‐Overexpressed Refractory Cancer
Jeeyun Lee
,
S. Kim
,
+10 authors
Y. Park
Clinical colorectal cancer
2018
Corpus ID: 3981245
2015
2015
Abstract 661: Increasing sensitivity of SAIT301, a specific monoclonal antibody of c-Met, with paclitaxel combination in c-Met positive gastric cancer
Sun Kyoung Kang
,
J. Kim
,
+7 authors
S. Rha
2015
Corpus ID: 79116921
The c-Met is frequently overexpressed and related to a worse prognosis in gastric carcinoma (GC). This study aimed to determine a…
Expand
2015
2015
Abstract 662: USP8 modulates ubiquitination of LRIG1 for Met degradation
Ji Min Lee
,
Bogyou Kim
,
Kyung-ah Kim
2015
Corpus ID: 58543687
The Met receptor tyrosine kinase is an attractive target for cancer therapy as it promotes invasive tumor growth. SAIT301 is a…
Expand
2014
2014
Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression
B-S Lee
,
S. Kang
,
+4 authors
C.-H. Kim
Cell Death and Disease
2014
Corpus ID: 10967505
Nasopharyngeal carcinoma (NPC) is a common malignant tumor with high invasive and metastatic potential. The hepatocyte growth…
Expand
Highly Cited
2014
Highly Cited
2014
Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody
J. M. Lee
,
B. Kim
,
+14 authors
K. A. Kim
Oncogene
2014
Corpus ID: 7384741
The Met receptor tyrosine kinase, found to be constitutively activated in many tumors, has become a leading target for cancer…
Expand
2014
2014
USP8 modulates ubiquitination of LRIG1 for Met degradation
Y. M. Oh
,
Saet Byoul Lee
,
+10 authors
Kyung-ah Kim
Scientific Reports
2014
Corpus ID: 12277727
The Met receptor tyrosine kinase is an attractive target for cancer therapy as it promotes invasive tumor growth. SAIT301 is a…
Expand
2014
2014
Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy
B. Kim
,
S. Wang
,
+15 authors
L. Weiner
Oncogene
2014
Corpus ID: 1441510
Met is a receptor tyrosine kinase that promotes cancer progression. In addition, Met has been implicated in resistance of tumors…
Expand
2014
2014
Abstract LB-219: Synthetic lethal screening reveals FGFR as one of combinatorial targets to overcome resistance to Met-targeted therapy
Bogyou Kim
2014
Corpus ID: 84851358
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Met is a receptor tyrosine kinase that promotes cancer…
Expand
2013
2013
Abstract 1036: Cbl-independent degradation of Met: Ways to avoid agonism of bivalent Met targeting antibody.
Ji Min Lee
,
Bogyou Kim
,
Kyung-ah Kim
2013
Corpus ID: 72002502
The Met receptor tyrosine kinase, found to be constitutively activated in many tumors, has become a leading target for cancer…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE